Skip to main content

Table 1 ncRNAs associated with anti-EGFR therapy resistance in CRC

From: Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy

NcRNAs Upregulated/downregulated Target References
miRNAs
miR-100 Upregulated DKK1, ZNRF3/Wnt/β-catenin pathway [41]
miR-125b Upregulated ZNRF3, RNF43, DKK3, APC2/Wnt/β-catenin pathway
p53
HER2
[41]
[46]
[47]
miR-7 Downregulated YY1
TYRO3, PI3K/AKT/mTOR pathway
EGFR
RAF-1
IGF1R
[49]
[50]
[51, 52]
[51]
[52]
miR-143 Downregulated Sos1, AKT, ERK
KRAS, RREB1
MAPK pathway
c-MYC
ADCC
[58]
[60]
[60]
[61]
[62]
miR-145 Downregulated RHBDD1, EGFR/RAF/MEK/ERK pathway
KRAS, RREB1
MAPK pathway
c-MYC
ADCC
[59]
[60]
[60]
[61]
[62]
miR-302a Downregulated CD44 [65]
miR-378 Downregulated RAS/RAF/MAPK pathway
ERK pathway
BRAF, RAS/RAF/MEK/ERK pathway
[66, 67]
[66, 67]
[68]
miR-193a-3p Downregulated KRAS, RAS/RAF pathway
MAPK pathway
Mcl1
[69]
[70]
[70]
miR-141-3p Downregulated EGFR, RAS/RAF1/ERK pathway
EGFR, AKT pathway
[71]
[71]
Let-7 Downregulated KRAS, MYC, IGF1, HMGA2 [72]
miR-375 Downregulated CTGF/EGFR/PIK3CA/AKT pathway
EGFR/KRAS/BRAF/ERK pathway
PHLPP1
[76]
[76]
[42]
miR-181d Downregulated PEAK1
KLK6
[81]
[80]
Upregulated FBXL3, CRY2
KRAS
[82]
[85]
miR-545 Downregulated EGFR
CDK4
MYO6
[86]
[87]
[88]
Upregulated RIG-I, PI3K/AKT pathway [90]
Other miRNAs that may be involved in anti-EGFR resistance
miR-181a Upregulated PTEN
WIF-1
[94]
[93]
miR-31-3p Upregulated E2F2, c-MYC pathway
RAS/MAPK pathway
[61, 96]
[61]
miR-31-5p Upregulated BRAF
Wnt/β-catenin pathway
[97]
[98]
miR-425-5p Upregulated BRAF/RAS/MAPK pathway
PI3K/AKT pathway
p53
CTNND1, Wnt/β-catenin pathway
[98]
[98]
[98]
[99]
miR-21 Upregulated 15-PGDH, EGFR pathway
PTEN, PI3K/AKT pathway
Wnt/β-catenin pathway
c-MYC
[100, 101]
[102,103,104]
[105]
[105]
miR-133b Downregulated EGFR [106]
miR-320d Downregulated PI3K/AKT/mTOR pathway
TUSC3
[111]
[111]
miR-192 Downregulated TRIP13, EGFR/AKT pathway
TRIP13, Wnt/β-catenin pathway
APC, c-Fos
[113]
[113]
[114]
miR-802 Downregulated EGFR, ERK pathway
EGFR, AKT pathway
[116]
[116]
miR-497 Downregulated IRS1, PI3K/AKT pathway
IRS1, MAPK pathway
IGF1R, PI3K/AKT pathway
PI3K/AKT/mTOR pathway
[117]
[117]
[118]
[119]
miR-4689 Downregulated KRAS, RAF/MEK/MAPK pathway
KRAS, RAF/MEK/ERK pathway
PI3K/AKT1 pathway
[120]
[120]
[120]
miR-130a-3p Downregulated WNT1 [121]
miR-708-5p Downregulated CD44, EGFR pathway
CTNNB1, Wnt/β-catenin pathway
PI3K/AKT pathway
[122]
[123]
[124]
miR-520a-3p Downregulated EGFR [125]
miR-342-3p Downregulated EGFR, BCL2 [127]
miR-215-5p Downregulated EREG, HOXB9 [128]
miR-99a Downregulated mTOR [130]
miR-200a Downregulated EphA2/EGFR/MAPK pathway [131]
miR-26b Downregulated EphA2/EGFR/MAPK pathway [131]
miR-875-5p Downregulated EGFR [134]
lncRNAs
MIR100HG Upregulated Wnt/β-catenin pathway [41, 44]
UCA1 Upregulated HGF/c-MET pathway [32]
CRART16 Upregulated ERBB3, ERBB3/MAPK pathway [33]
LINC00973 Upregulated / [152]
SLCO4A1-AS1 Upregulated EGFR/MAPK pathway
Wnt/β-catenin pathway
c-MYC pathway
[153]
[154]
[155]
TTN-AS1 Upregulated PI3K/AKT/mTOR pathway [119]
POU5F1P4 Downregulated PI3K/AKT pathway [157]
Other lncRNAs that may be involved in anti-EGFR resistance
HOTAIR Upregulated EGFR
FUT6, PI3K/AKT/mTOR pathway
[86]
[158]
ZEB1-AS1 Upregulated β-catenin, Wnt/β-catenin pathway [160]
TCF4, MYC, MMP-7, cyclin D1 [160]
CRNDE Upregulated β-catenin, TCF4, Wnt/β-catenin pathway [161]
DNAJC3-AS1 Upregulated EGFR/PI3K/AKT pathway [162]
LINC00265 Upregulated Wnt/β-catenin pathway
EGFR
[163]
[163]
LOXL1-AS1 Upregulated CD44, EGFR pathway [122]
MINCR Upregulated CTNNB1, Wnt/β-catenin pathway [123]
SCARNA2 Upregulated EGFR, BCL-2 [127]
circRNAs
circHIPK3 Upregulated EGFR, MEK/ERK pathway
IGF1R, PI3K/AKT pathway
YY1, β-catenin pathway
[184]
[184]
[184, 186]
CDR1as Upregulated EGFR, IGF1R [52]
circRNA_0000392 Upregulated PIK3R3, AKT/mTOR pathway [188]